---
title: "Apimeds Secures Forbearance to Support Listing Remediation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285062952.md"
description: "Apimeds Pharmaceuticals US, Inc. has secured a forbearance agreement from its senior noteholder, Alto Opportunity Master Fund, until June 30, 2026, as part of its strategy to address listing compliance issues. The company recently reached a confidential settlement with Inscobee Inc. and Apimeds Korea, resolving disputes from a previous merger and ensuring a $4 million working capital contribution. The agreement includes conditions for SEC filings, NYSE compliance, and a reverse stock split, emphasizing the importance of executing its remediation and listing strategy to maintain its NYSE American listing."
datetime: "2026-05-04T10:50:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285062952.md)
  - [en](https://longbridge.com/en/news/285062952.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285062952.md)
---

# Apimeds Secures Forbearance to Support Listing Remediation

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Apimeds Pharmaceuticals US, Inc. ( (APUS) ) just unveiled an update.

On April 24, 2026, Apimeds Pharmaceuticals US, Inc. and its affiliates entered into a confidential settlement with South Korea’s Inscobee Inc. and Apimeds Korea that resolves all disputes related to a December 1, 2025 merger, preserves Lokahi’s ownership of the Apitox program, and secures a $4 million working capital contribution plus debt forgiveness for Apimeds. The deal also restructures Lokahi’s ownership, mandates creation and future spin-off of a new subsidiary, validates prior support and voting agreements while voiding contested stockholder consents, resets the board transition process, and commits all parties to advance pending corporate actions contingent on NYSE American lifting a trading halt and approving the company’s listing application.

A related side letter introduces potential remedies, including a possible merger unwind, if Apimeds misses key 2025 Form 10-K filing or audit milestones, while mutual releases and planned dismissal of litigation eliminate legacy legal overhang once Lokahi funds the working capital. On April 30, 2026, Apimeds further stabilized its capital structure by securing a forbearance agreement from its senior noteholder Alto Opportunity Master Fund through June 30, 2026, tying waiver of existing defaults to strict conditions on SEC filings, NYSE compliance, a 1-for-10 reverse stock split, registration effectiveness, and board reconstitution, underscoring the company’s reliance on successful execution of its remediation and listing strategy.

**More about Apimeds Pharmaceuticals US, Inc.**

Apimeds Pharmaceuticals US, Inc. operates in the biopharmaceutical sector, focusing on drug development programs including the Apitox program held through its subsidiary Lokahi Therapeutics. The company is also aligned with technology-focused subsidiary MindWave Innovations and is seeking to maintain its NYSE American listing, support investor financing arrangements, and manage complex capital structure matters involving preferred stock, convertible notes, and equity incentive plans.

**Average Trading Volume:** 170,962

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $23.64M

For a thorough assessment of APUS stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [APUS.US](https://longbridge.com/en/quote/APUS.US.md)

## Related News & Research

- [AleAnna, Inc. Reports First Quarter 2026 Results | ANNA Stock News](https://longbridge.com/en/news/286463118.md)
- [Faron Pharmaceuticals LTD: Holding(s) In Company](https://longbridge.com/en/news/286725255.md)
- [Capstone Companies, Inc. announces Execution of Binding Letter of Intent with eBliss Global, Inc. | CAPC Stock News](https://longbridge.com/en/news/286782166.md)
- [Vishay Intertechnology, Inc. $VSH Shares Bought by Dana Investment Advisors Inc.](https://longbridge.com/en/news/286733016.md)
- [NorthStrive® Companies Inc. Co-Advises on Acquisition of A&B Aerospace, Inc.](https://longbridge.com/en/news/286804790.md)